<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02252367</url>
  </required_header>
  <id_info>
    <org_study_id>ANDRO-AOUC-2014-01</org_study_id>
    <nct_id>NCT02252367</nct_id>
  </id_info>
  <brief_title>Effect of 12 Weeks Treatment With Tadalafil vs Placebo on Lower Urinary Tract Symptoms</brief_title>
  <official_title>Double-blind, Placebo-controlled Study on Men With Lower Urinary Tract Symptoms to Assess Changes in Pressure Flow Study and in Molecular Profile of Prostatic Tissue After 12 Weeks Treatment With Tadalafil.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florence</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Florence</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      At present time several preclinical and clinical study have demonstrated the safety and
      efficacy of PDE5 (phosphodiesterase type 5)-inhibitors for LUTS/BPH (lower urinary tract
      symptoms/benign prostatic hyperplasia) patients with or without erectile dysfunction.
      However, the link between clinical outcomes (symptoms scores), functional activity
      (urodynamic findings) and molecular pathways, in particular regarding inflammatory pattern
      (molecular analyses), has not been previously investigated.

      Aim of present study is to assess, for the first time in literature, changes in pressure flow
      study (PFS) and changes in molecular profile of prostatic tissue (inflammatory and tissue
      remodeling markers) in men treated for 12 weeks with tadalafil 5 mg compared with placebo and
      to correlate these data with changes in symptoms scores (IPSS, International Prostatic
      Symptoms Score) in men with LUTS secondary to BPH refractory to alpha blockers.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2015</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of LUTS/BPH symptoms</measure>
    <time_frame>12 weeks</time_frame>
    <description>BPH-associated inflammatory symptoms will be assessed by using the National Institute of Health Chronic Prostatitis Symptom Index (NIH-CPSI). BPH-associated LUTS will be assessed by using International Prostate Symptom Score (IPSS).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement of pressure flow study (PFS) parameters</measure>
    <time_frame>12 weeks</time_frame>
    <description>Maximum flow rate (Qmax), average flow rate (Qave), voided volume (Vcomp), post void residual volume (PVR) will be evaluated. An abdominal ultrasound immediately after voiding for uroflowmetry will be performed in order to determine the PVR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volumetric change of the prostate</measure>
    <time_frame>12 weeks</time_frame>
    <description>Prostate volume as assessed by transrectal ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in prostate inhomogeneity and in the number of prostatic macrocalcifications</measure>
    <time_frame>12 weeks</time_frame>
    <description>BPH-associated prostate inhomogeneity and presence of micro-calcifications will be assessed by using male genital tract male genital tract colour-Doppler ultrasonography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation in genic expression of prostatic inflammation markers</measure>
    <time_frame>12 weeks</time_frame>
    <description>BPH-associated prostate inflammation, fibrosis, and hypoxia will be measured by immunohistochemical and quantitative RT-PCR (qRT-PCR) analyses of inflammatory-, fibrosis- and hypoxia-related markers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation in serum inflammation markers CRP (C-reactive protein) and ESR (Erythrocyte Sedimentation Rate)</measure>
    <time_frame>12 weeks</time_frame>
    <description>CRP measured on serum and ESR measured on blood drawn at baseline and after 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in metabolic profile</measure>
    <time_frame>12 weeks</time_frame>
    <description>Metabolic parameters will be evaluated (glycaemia, insulinemia, total cholesterol, HDL, triglycerides, HbA1c, mean arterial pressure, waist circumference, body mass index)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Variation in seminal plasma IL-8 (interleukin-8) levels</measure>
    <time_frame>12 weeks</time_frame>
    <description>Seminal IL-8, a chemokine involved in male genital tract infection/inflammation, will be evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in erectile function</measure>
    <time_frame>12 weeks</time_frame>
    <description>Erectile function will be assessed by using the International Index of Erectile Function-5 (IIEF-5) score.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Prostatic Hyperplasia</condition>
  <condition>Lower Urinary Tract Symptoms</condition>
  <arm_group>
    <arm_group_label>Tadalafil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>43 male subjects affected by BPH (benign prostatic hyperplasia) planned for simple prostatectomy will be randomized to tadalafil 5 mg - 1 film-coated tablet orally once daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>43 male subjects affected by BPH (benign prostatic hyperplasia) planned for simple prostatectomy will be randomized to placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tadalafil</intervention_name>
    <description>Tadalafil 5 mg once daily for 12 weeks.</description>
    <arm_group_label>Tadalafil</arm_group_label>
    <other_name>Cialis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet once daily for 12 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult male subjects planned to undergo simple prostatectomy (TURP, Transurethral
             resection of the prostate, or open prostatectomy) for benign prostatic hyperplasia;

          -  treatment with alpha-blockers (Tamsulosin 0.4 mg/die)

          -  being capable of giving informed consent.

        Exclusion Criteria:

          -  participation in another clinical study;

          -  known or suspected presence of prostatic cancer or PSA (prostate specific antigen)
             value &gt;10 ng/mL;

          -  suspected lack of the participant's compliance;

          -  known severe allergies or hypersensitivity to the study drug (active substance or
             excipients of the formulation);

          -  nown neurogenic bladder (i.e. Parkinson's disease);

          -  suspected or proven urinary infections;

          -  presence of bladder stone.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mario Maggi</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florence</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mario Maggi</last_name>
    <email>m.maggi@dfc.unifi.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinica Urologica - Azienda Ospedaliero-Universitaria Careggi</name>
      <address>
        <city>Florence</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario Maggi</last_name>
      <email>m.maggi@dfc.unifi.it</email>
    </contact>
    <investigator>
      <last_name>Mauro Gacci</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Linda Vignozzi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marco Carini</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Gacci M, Corona G, Salvi M, Vignozzi L, McVary KT, Kaplan SA, Roehrborn CG, Serni S, Mirone V, Carini M, Maggi M. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol. 2012 May;61(5):994-1003. doi: 10.1016/j.eururo.2012.02.033. Epub 2012 Feb 25. Review.</citation>
    <PMID>22405510</PMID>
  </reference>
  <reference>
    <citation>Gacci M, Vittori G, Tosi N, Siena G, Rossetti MA, Lapini A, Vignozzi L, Serni S, Maggi M, Carini M. A randomized, placebo-controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0.4 mg vs. tamsulosin 0.4 mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Sex Med. 2012 Jun;9(6):1624-33. doi: 10.1111/j.1743-6109.2012.02718.x. Epub 2012 Apr 17.</citation>
    <PMID>22510238</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2014</study_first_submitted>
  <study_first_submitted_qc>September 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2014</study_first_posted>
  <last_update_submitted>October 25, 2017</last_update_submitted>
  <last_update_submitted_qc>October 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Florence</investigator_affiliation>
    <investigator_full_name>Mario Maggi</investigator_full_name>
    <investigator_title>Full Professor of Endocrinology</investigator_title>
  </responsible_party>
  <keyword>Phosphodiesterase 5 Inhibitors</keyword>
  <keyword>BPH/LUTS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Lower Urinary Tract Symptoms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tadalafil</mesh_term>
    <mesh_term>Phosphodiesterase 5 Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

